Oscar Health, Inc.
NYSE:OSCRMedical - Healthcare Plans
+$0.05 today
- Market cap
- $7.15B
- Beta
- 2.39
- P/E (TTM)
- -214.2
- EPS (TTM)
- -$0.13
Volume 7.38M
Average 7.51M
OSCR Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Oscar Health, Inc.NYSE: OSCR
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue growth accelerates
Q2 FY2026 revenue of $4.88B rose 70.4% year over year, ahead of the +42.8% change in trailing-twelve-month revenue. Sequentially, it rose 5.0% from the prior quarter. Over 3 fiscal years it compounded at +41.6% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 6 analysts of $18.89B (+61.5%) for the fiscal year ending Dec 2026, a step up from the +27.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $4.88B+5.0% QoQ
- Last fiscal yearDec 2025
- $11.7B+27.5% YoY
- LTMJun 2026
- $15.32B+42.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +70.4% | +57.2% | -13.2 pp |
| 1 year | +27.5% | +61.5% | +34.0 pp |
| 3-year CAGR | +41.6% | +27.8% | -13.8 pp |
| 5-year CAGR | +22.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 11.7B USD
- Year-over-year change
- +27.5%
- 4-year CAGR
- +57.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.7B | +27.5% |
| FY2024 | 2024-12-31 | 9.18B | +56.5% |
| FY2023 | 2023-12-31 | 5.86B | +42.1% |
| FY2022 | 2022-12-31 | 4.13B | +114.8% |
| FY2021 | 2021-12-31 | 1.92B | — |
Revenue vs competitors
How OSCR compares with its peers on the latest reported figures
- OSCR's LTM Jun 2026 revenue of $15.32B is the 6th highest of the 8 companies compared; the peer median is $193.73B.
- Its year-over-year change of +42.8% is the 2nd highest of 8, against a peer median of +7.4%.
- Over three fiscal years its annual growth of +41.6% compares with a peer median of +12.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $415.09B | +7.4% | +7.6% | |
| LTM Sep 2026 | $286.32B | +6.8% | +15.1% | |
| LTM Sep 2026 | $201.83B | +3.6% | +8.3% | |
| LTM Jun 2026 | $193.73B | +8.7% | +10.5% | |
| LTM Sep 2026 | $43.63B | -2.1% | +12.4% | |
| LTM Jun 2026 | $15.32B | +42.8% | +41.6% | |
| LTM Mar 2026 | $4.26B | +41.8% | +40.2% | |
| LTM Jun 2026 | $2.48B | +54.0% | +20.6% | |
| Peer median (excluding OSCR) | $193.73B | +7.4% | +12.4% | |
Competitors are the stored peer set for OSCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.92B | 4.13B | 5.86B | 9.18B | 11.7B |
| Cost of Revenue | 0 | 0 | 4.64B | 7.33B | 10.02B |
| Gross Profit | 1.92B | 4.13B | 1.22B | 1.84B | 1.68B |
| Gross Margin | 100.0% | 100.0% | 20.8% | 20.1% | 14.4% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 265.08M | 1.42B | 0 | 0 | 2.05B |
| Operating Expenses | 2.49B | 4.74B | 1.46B | 1.79B | 2.08B |
| Depreciation & Amortization | 14.61M | 15.28M | 30.69M | 32.15M | 28.89M |
| EBITDA | (551.26M) | (572.17M) | (212M) | 89.31M | (391.05M) |
| EBITDA Margin | -28.7% | -13.9% | -3.6% | 1.0% | -3.3% |
| Operating Income | (570.58M) | (610.08M) | (235.62M) | 57.27M | (396.36M) |
| Operating Margin | -29.7% | -14.8% | -4.0% | 0.6% | -3.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.72M | 22.62M | 24.6M | 23.73M | 17.6M |
| Other Income / Expenses | 0 | 0 | (31.69M) | (23.84M) | (40.94M) |
| Income Before Tax | (570.58M) | (610.08M) | (267.3M) | 33.43M | (437.3M) |
| Pre-Tax Margin | -29.7% | -14.8% | -4.6% | 0.4% | -3.7% |
| Income Tax Expense | 846K | (523K) | 3.29M | 7.31M | 5.61M |
| Net Income | (572.61M) | (606.28M) | (270.73M) | 25.43M | (443.15M) |
| Net Margin | -29.8% | -14.7% | -4.6% | 0.3% | -3.8% |
| EPS (Basic) | (3.19) | (2.85) | (1.22) | 0.11 | (1.69) |
| EPS (Diluted) | (3.19) | (2.85) | (1.22) | 0.10 | (1.69) |
| Weighted Avg Shares | 178.97M | 212.47M | 221.66M | 240.39M | 262.39M |
| Weighted Avg Shares (Diluted) | 178.97M | 212.47M | 221.66M | 265.85M | 262.39M |
Oscar Health, Inc.
NYSE:OSCR
Intrinsic Alpha fair value
Locked
Current Price
$27.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.